Ditte Boilesen (Denmark)
Laboratory for Experimental Vaccinology, Centre for medical parasitology ISIM, University of Copenhagen
Presenter of 1 Presentation
THERAPEUTICAL REMOVAL OF PRE-EXISTING PAPILLOMAVIRUS INFECTION IN RHESUS MACAQUES BY VACCINATION WITH ADENOVIRAL VECTOR (ID 791)
Session Time
08:45 - 10:15
Session Type
Basic Science Oral Session
Lecture Time
10:00 - 10:12
[{"name":"THERAPEUTICAL REMOVAL OF PRE-EXISTING PAPILLOMAVIRUS INFECTION IN RHESUS MACAQUES BY VACCINATION WITH ADENOVIRAL VECTOR \u003Csmall\u003E(ID 791)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":791,"presentation":"THERAPEUTICAL REMOVAL OF PRE-EXISTING PAPILLOMAVIRUS INFECTION IN RHESUS MACAQUES BY VACCINATION WITH ADENOVIRAL VECTOR \u003Csmall\u003E(ID 791)\u003C\/small\u003E","session":"Oral Session 4: Vaccines and New Treatment Approaches","presenter":"Ditte Boilesen (Denmark)","photo":""},"playlist":[{"name":"THERAPEUTICAL REMOVAL OF PRE-EXISTING PAPILLOMAVIRUS INFECTION IN RHESUS MACAQUES BY VACCINATION WIT","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/23\/791 Ditte Boilesen.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/23\/791 Ditte Boilesen.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/23\/BC52FE06.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/23\/791 Ditte Boilesen.vtt"}]}]
{"provider":"CTI","provider_live":0,"type":1,"code":"8E22UU0eD"}
[session]
[presentation]
[presenter]
Moderator of 1 Session
Session Type
Basic Science Oral Session
Session Time
08:45 - 10:15
[{"name":"ATOMIC LAYER DEPOSITION TECHNOLOGY FOR PREPARING SINGLE-SHOT, THERMOSTABLE HUMAN PAPILLOMAVIRUS VACCINES. \u003Csmall\u003E(ID 427)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":427,"presentation":"ATOMIC LAYER DEPOSITION TECHNOLOGY FOR PREPARING SINGLE-SHOT, THERMOSTABLE HUMAN PAPILLOMAVIRUS VACCINES. \u003Csmall\u003E(ID 427)\u003C\/small\u003E","session":"Oral Session 4: Vaccines and New Treatment Approaches","presenter":"Robert L. Garcea (United States of America)","photo":""},"playlist":[{"name":"ATOMIC LAYER DEPOSITION TECHNOLOGY FOR PREPARING SINGLE-SHOT, THERMOSTABLE HUMAN PAPILLOMAVIRUS VACC","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/23\/Robert L Garcea - IPVC20 - PRESENTATION id 427.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/23\/Robert L Garcea - IPVC20 - PRESENTATION id 427.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/23\/3B534A55.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/23\/Robert L Garcea - IPVC20 - PRESENTATION id 427.vtt"}]},{"name":"SENSITIVITY OF HUMAN PAPILLOMAVIRUS (HPV) LINEAGE AND SUBLINEAGE VARIANT PSEUDOVIRUSES TO NEUTRALIZATION BY NONAVALENT VACCINE ANTIBODIES \u003Csmall\u003E(ID 410)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":410,"presentation":"SENSITIVITY OF HUMAN PAPILLOMAVIRUS (HPV) LINEAGE AND SUBLINEAGE VARIANT PSEUDOVIRUSES TO NEUTRALIZATION BY NONAVALENT VACCINE ANTIBODIES \u003Csmall\u003E(ID 410)\u003C\/small\u003E","session":"Oral Session 4: Vaccines and New Treatment Approaches","presenter":"Simon Beddows (United Kingdom)","photo":""},"playlist":[{"name":"Simon Beddows - IPVC20 - 410 -Ready","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/23\/Simon Beddows - IPVC20 - 410 -Ready-.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/23\/Simon Beddows - IPVC20 - 410 -Ready-.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/23\/F87ACDB8.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/23\/Simon Beddows - IPVC20 - 410 -Ready-.vtt"}]},{"name":"TOWARDS A CGMP-GRADE CHIMERIC PAPILLOMAVIRUS VACCINE: PROTECTION OVER ONE YEAR OF HPV16 RG-1 VLP COMPARED TO A GARDASIL-9 VACCINATION IN PRE-CLINICAL PAPILLOMAVIRUS ANIMAL MODELS \u003Csmall\u003E(ID 437)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":437,"presentation":"TOWARDS A CGMP-GRADE CHIMERIC PAPILLOMAVIRUS VACCINE: PROTECTION OVER ONE YEAR OF HPV16 RG-1 VLP COMPARED TO A GARDASIL-9 VACCINATION IN PRE-CLINICAL PAPILLOMAVIRUS ANIMAL MODELS \u003Csmall\u003E(ID 437)\u003C\/small\u003E","session":"Oral Session 4: Vaccines and New Treatment Approaches","presenter":"Joshua W. Wang (United States of America)","photo":""},"playlist":[{"name":"TOWARDS A CGMP-GRADE CHIMERIC PAPILLOMAVIRUS VACCINE: PROTECTION OVER ONE YEAR OF HPV16 RG-1 VLP COM","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/23\/Joshua Wang - IPVC20 - presentation 437.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/23\/Joshua Wang - IPVC20 - presentation 437.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/23\/3868022A.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/23\/Joshua Wang - IPVC20 - presentation 437.vtt"}]},{"name":"TARGETING DNA DAMAGE RESPONSE AS A STRATEGY TO TREAT HPV INFECTIONS \u003Csmall\u003E(ID 945)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":945,"presentation":"TARGETING DNA DAMAGE RESPONSE AS A STRATEGY TO TREAT HPV INFECTIONS \u003Csmall\u003E(ID 945)\u003C\/small\u003E","session":"Oral Session 4: Vaccines and New Treatment Approaches","presenter":"Thomas R. Broker (United States Minor Outlying Islands)","photo":""},"playlist":[{"name":"TARGETING DNA DAMAGE RESPONSE AS A STRATEGY TO TREAT HPV INFECTIONS","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/23\/IPVC 20 - P945 - S670 - N. Sanjib Banerjee .mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/23\/IPVC 20 - P945 - S670 - N. Sanjib Banerjee .mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/23\/1D9FC5A1.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/23\/IPVC 20 - P945 - S670 - N. Sanjib Banerjee .vtt"}]},{"name":"FIRST EXAMPLE OF CURING CANCER USING CRISPR\/CAS GENE EDITING. TREATING HPV CANCERS IN PRECLINICAL ANIMAL MODELS. \u003Csmall\u003E(ID 703)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":703,"presentation":"FIRST EXAMPLE OF CURING CANCER USING CRISPR\/CAS GENE EDITING. TREATING HPV CANCERS IN PRECLINICAL ANIMAL MODELS. \u003Csmall\u003E(ID 703)\u003C\/small\u003E","session":"Oral Session 4: Vaccines and New Treatment Approaches","presenter":"Nigel A. McMillan (Australia)","photo":""},"playlist":[{"name":"FIRST EXAMPLE OF CURING CANCER USING CRISPR\/CAS GENE EDITING. TREATING HPV CANCERS IN PRECLINICAL AN","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/23\/GMT20200619-044818_Nigel-McMi_2560x1440.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/23\/GMT20200619-044818_Nigel-McMi_2560x1440.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/23\/D9E62765.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/23\/GMT20200619-044818_Nigel-McMi_2560x1440.vtt"}]},{"name":"LONG-TERM HPV-SPECIFIC IMMUNE RESPONSE AFTER ONE VERSUS TWO AND THREE DOSES OF BIVALENT HPV VACCINATION IN DUTCH GIRLS \u003Csmall\u003E(ID 204)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":204,"presentation":"LONG-TERM HPV-SPECIFIC IMMUNE RESPONSE AFTER ONE VERSUS TWO AND THREE DOSES OF BIVALENT HPV VACCINATION IN DUTCH GIRLS \u003Csmall\u003E(ID 204)\u003C\/small\u003E","session":"Oral Session 4: Vaccines and New Treatment Approaches","presenter":"Hella Pasmans (Netherlands)","photo":""},"playlist":[{"name":"LONG-TERM HPV-SPECIFIC IMMUNE RESPONSE AFTER ONE VERSUS TWO AND THREE DOSES OF BIVALENT HPV VACCINAT","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/23\/Hella Pasmans - IPVC20- Presentation 204.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/23\/Hella Pasmans - IPVC20- Presentation 204.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/23\/94417329.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/23\/Hella Pasmans - IPVC20- Presentation 204.vtt"}]},{"name":"THERAPEUTICAL REMOVAL OF PRE-EXISTING PAPILLOMAVIRUS INFECTION IN RHESUS MACAQUES BY VACCINATION WITH ADENOVIRAL VECTOR \u003Csmall\u003E(ID 791)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":791,"presentation":"THERAPEUTICAL REMOVAL OF PRE-EXISTING PAPILLOMAVIRUS INFECTION IN RHESUS MACAQUES BY VACCINATION WITH ADENOVIRAL VECTOR \u003Csmall\u003E(ID 791)\u003C\/small\u003E","session":"Oral Session 4: Vaccines and New Treatment Approaches","presenter":"Ditte Boilesen (Denmark)","photo":""},"playlist":[{"name":"THERAPEUTICAL REMOVAL OF PRE-EXISTING PAPILLOMAVIRUS INFECTION IN RHESUS MACAQUES BY VACCINATION WIT","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/23\/791 Ditte Boilesen.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/23\/791 Ditte Boilesen.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/23\/BC52FE06.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/23\/791 Ditte Boilesen.vtt"}]}]
{"type":2,"code":"6E32UU0p"}
[session]
[presentation]
[presenter]
